Spyre Therapeutics is no longer a discovery story. Three open-label induction readouts in ulcerative colitis and a mixed rheumatoid arthritis basket have moved the equity from a cash-rich option into a priced combination platform. The market is treating half-life-extended antibodies against three validated immunology targets as if the combination thesis is already earned. Controlled combination data do not arrive until next year. That gap between priced conviction and placebo-controlled evidence is the entire investment debate.
The open-label SKYLINE monotherapies produced large Robarts index declines and remission rates that looked competitive with approved colitis classes. Merck then delivered the first registrational TL1A win in colitis, which validated the target even as it raised the competitive bar. The first placebo-controlled Spyre readout, the SKYWAY rheumatoid arthritis sub-study, cleared statistical significance but missed the internal bar for monotherapy development. Net loss printed at $36 million only because a $40 million legacy milestone offset operating spend. Cash ended the quarter at $1145 million. That pile funds operations deep into the second half of the decade. Enterprise value already capitalizes a successful combination franchise.
Whether Part B of SKYLINE can convert open-label monotherapy signals into placebo-adjusted combination superiority is the variable that resolves the multiple. Psoriatic arthritis and axial spondyloarthritis readouts later this year test whether TL1A still has a rheumatology path after the rheumatoid arthritis miss. Share prices near $90 already treat combination success as the base case. The question for holders is simple. Is the current capitalization paying for a de-risked three-mechanism combination platform, or for uncontrolled induction snapshots that shrink once a shared placebo arm arrives?